ArticleJournal of nanobiotechnology2025
Astragalus polysaccharide-based nano-platforms loading PTX to boost chemo-immunotherapy for triple-negative breast cancer with intrinsic GLUT-targeting ability and immunoregulatory activity.
Article in Journal of nanobiotechnology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed.
- Microbiota-derived self-adjuvanting exopolysaccharide-based codelivery system for potent cancer immunotherapy.Materials today. Bio · 2026Article
- New insights into breast cancer therapy: application and mechanisms of novel targeted nano-formulation.International journal of pharmaceutics: X · 2026Review
- Environment-Responsive Sustained-Release Nanoparticles for the Protection, Delivery and Release of Clove Essential Oil to Improve Foodborne Bacterial Colitis Treatment.Advanced healthcare materials · 2026Article
- Traditional Chinese Medicine Polysaccharides-Based Nano-Drug Delivery Systems: Design Strategies and Combination Platforms in Tumor Therapy.Life (Basel, Switzerland) · 2026Review
- Natural polysaccharides as immune adjuvants to overcome immune checkpoint inhibitor resistance: mechanistic insights, clinical evidence, and translational challenges.Frontiers in immunology · 2026Review
- Quercetin attenuates skin inflammation and fibrosis in systemic sclerosis by targeting the RELA/c-Jun axis to suppress th17 cell responses.Frontiers in immunology · 2026Article
- Programmable Self-Assembly of Traditional Chinese Medicine (TCM) Monomers: From Molecular Mechanisms to Multifunctional Nanomedicine.International journal of nanomedicine · 2026Review
- Natural supplements in breast cancer therapy: translational evidence, clinical safety, and emerging challenges.Frontiers in oncology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Chemo-immunotherapy shows great promises for triple-negative breast cancer (TNBC) treatment, including PTX. However, the chemo-immunotherapy of PTX is limited, due to its upregulation of PD-L1 expression on tumor cells and bone marrow suppression. In addition, nano drug delivery systems of PTX encounter substantial challenges against tumors, such as inefficient encapsulation and inadequate tumor targeting efficacy. Here, PTX-loaded nanoparticles (APS-PTX NPs) based on astragalus polysaccharide (APS) was successfully developed to address these challenges. In APS-PTX NPs, APS could form amphiphilic polymers to highly load PTX, in which APS worked as the carrier, active targeting ligand, immunoregulator and chemotherapy adjuvant at the same time. Compared to PTX or Lipusu
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.